A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects
Ellen Kraig(The University of Texas at San Antonio Health Science Center), Dean L. Kellogg(The University of Texas Health Science Center at Houston), Laura K. Chiodo(The University of Texas at San Antonio Health Science Center), Nicolas Musi(Cedars-Sinai Medical Center), Hanyu Liang(The University of Texas at San Antonio Health Science Center), Martin A. Javors(The University of Texas at San Antonio Health Science Center), Adriana D. Benavides(The University of Texas at San Antonio Health Science Center), Tyler J. Curiel(Tulane University), Wouter Koek(The University of Texas at San Antonio Health Science Center), Terry Romo(The University of Texas at San Antonio Health Science Center), Qianqian Liu(The University of Texas at San Antonio Health Science Center), Leslie A. Linehan(The University of Texas at San Antonio Health Science Center), Yubo Wu(The University of Texas at San Antonio Health Science Center), Jonathan Gelfond(The University of Texas at San Antonio Health Science Center)
Cited by 168
Related Papers
Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
|EBioMedicine|2019|1.2k
Interventions to Slow Aging in Humans: Are We Ready?
|Aging Cell|2015|598
Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma
|Cancer Research|2016|399
Combined autophagy and HDAC inhibition
|Autophagy|2014|292